Community-Engaged Trial to Increase COVID-19 Vaccine Uptake in Black Individuals with Rheumatic Conditions
Published in BMJ Open, August 24, 2024
Background: In the US, there are disparities in COVID-19 infection and vaccine uptake among historically marginalized racial and ethnic groups. People with rheumatic conditions, especially those who are immunocompromised, are at higher risk for severe infection, with significant racial inequities in outcomes and vaccine uptake. Structural racism and misinformation contribute to these inequities.
Method: A community-based trial comparing the effectiveness of training trusted community leaders with rheumatic conditions using a racial justice vs a biomedical framework to increase COVID-19 vaccine uptake and reduce hesitancy. The trial began in February 2024 in Boston and Chicago. Eligible community leaders will receive specific training and then disseminate the information to their social network members.
Outcome: The primary outcome will be the COVID-19 vaccine uptake among the social network members of the trained community leaders, compared between the two intervention groups.
Results: The trial has received ethical approval and will be published in a peer-reviewed journal.
Trial Registration Number: NCT05822219
PMID: 39181556 | DOI: 10.1136/bmjopen-2024-087918
DocSym: Simplifying Clinical Practice
Clinical trials are essential for developing safe treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research, making it easily accessible for clinicians to apply in everyday medical practice.
Streamlining Healthcare Operations with AI
In today’s healthcare environment, our mobile apps support scheduling, treatment monitoring, and telemedicine to improve patient care and expand services digitally.
AI can enhance clinic workflows, improve patient outcomes, and reduce paper-based routines. Learn more at aidevmd.com.
